Mammoth Biosciences is a technology company.
Mammoth Biosciences has raised $263.1M across 5 funding rounds.
Key people at Mammoth Biosciences.
Mammoth Biosciences has raised $263.1M in total across 5 funding rounds.
Key people at Mammoth Biosciences.
Mammoth Biosciences is a biotechnology company developing ultracompact CRISPR systems for in vivo gene editing therapies targeting life-threatening diseases, alongside diagnostics applications.[1][3][4] Founded in 2017, it focuses on curative treatments by enabling precise editing in hard-to-reach tissues using modalities like base editing, gene writing, and epigenetic editing, serving patients with genetic disorders and partnering with pharma giants.[1][2][4] The company has raised over $195 million, achieving unicorn status in 2021 via a $150 million Series D, with 190 employees and a pipeline including lead candidate MB-111 for liver triglyceride regulation.[1][2][4]
Its growth momentum includes preclinical advancements, such as presenting MB-111 data at the 2025 ESGCT Congress, DARPA and NIH funding for multi-pathogen diagnostics, and a GSK partnership for rapid COVID-19 tests, positioning it as a CRISPR leader against competitors like CRISPR Therapeutics and Intellia.[1][2][4]
Mammoth Biosciences was founded in 2017 by CRISPR pioneer and Nobel laureate Jennifer Doudna, alongside Trevor Martin, Janice Chen (current Co-founder and CTO), and Lucas Harrington.[1][3][4] Doudna's groundbreaking work on CRISPR-Cas9, which earned her the 2020 Nobel Prize in Chemistry, inspired the venture to expand beyond traditional systems.[1][2] The idea emerged from identifying nature's diverse CRISPR enzymes to create smaller, more versatile tools for in-body editing, addressing limitations of bulkier Cas9 proteins.[1][4]
Early traction came swiftly: by 2021, it secured unicorn valuation with $195 million in funding, including Amazon's participation, and government grants for diagnostics like 20-minute COVID tests and multi-pathogen detection.[2] Pivotal moments include partnerships with GSK and pharma leaders, building a robust IP portfolio from deep science expertise.[1][2][4]
Mammoth rides the CRISPR therapeutics wave, transforming genetic medicine from ex vivo edits to scalable in vivo cures amid rising demand for one-time treatments for diseases like hypertriglyceridemia.[2][4][6] Timing aligns with maturing delivery tech (e.g., lipid nanoparticles) and regulatory progress, fueled by post-Nobel validation and AI-aided protein engineering.[1][2] Market forces favor it: exploding gene therapy funding, diagnostics needs from pandemics, and competition pushing innovation, with Mammoth's compact systems offering packaging advantages.[1][2]
It influences the ecosystem by licensing tech, partnering with big pharma, and advancing diagnostics, accelerating CRISPR's shift from hype to clinic while challenging incumbents through biodiversity-sourced enzymes.[1][4][5]
Mammoth is poised for clinical milestones, with MB-111 preclinical data signaling 2026+ trials and pipeline expansion into more indications via partnerships.[4] Trends like advanced delivery, multimodal editing, and AI-protein design will amplify its edge, potentially yielding first approvals amid a $100B+ gene therapy market.[1][2] Its influence may evolve from platform pioneer to category leader, unlocking CRISPR's full promise for millions—echoing Doudna's vision that began with biological scissors now reshaping human health.[6]
Mammoth Biosciences has raised $263.1M in total across 5 funding rounds.
Mammoth Biosciences's investors include Cubit Investments Ltd, Founders Fund, Insight Partners, Long Journey Ventures, NFX, O.G. Tech Partners, Sarona Ventures, Khosla Ventures, KittyHawk Ventures, Kleiner Perkins, Plum Alley Investments, Esther Dyson.
Mammoth Biosciences has raised $263.1M across 5 funding rounds. Most recently, it raised $150.0M Series D in September 2021.
